Predictive biomarker for cancer treatment with ADCC-enhanced antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9360481
APP PUB NO 20140227256A1
SERIAL NO

14159895

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AG8952 SCHLIEREN-ZUERICH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Di, Scala Lilla Basel, CH 1 2
Evers, Stefan Muellheim, DE 40 195
Gerdes, Christian Erlenbach/ZH, CH 18 169
Mancao, Christoph Weil am Rhein, DE 1 2
Passioukov, Alexandre Zuerich, CH 3 31
Umana, Pablo Wollerau, CH 241 4504

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 7, 2023
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 7, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00